title: Rapid target-specific remodeling of fast-spiking inhibitory circuits after loss of dopamine.
abstract: In Parkinson's disease (PD), dopamine depletion alters neuronal activity in the direct and indirect pathways and leads to increased synchrony in the basal ganglia network. However, the origins of these changes remain elusive. Because GABAergic interneurons regulate activity of projection neurons and promote neuronal synchrony, we recorded from pairs of striatal fast-spiking (FS) interneurons and direct- or indirect-pathway MSNs after dopamine depletion with 6-OHDA. Synaptic properties of FS-MSN connections remained similar, yet within 3 days of dopamine depletion, individual FS cells doubled their connectivity to indirect-pathway MSNs, whereas connections to direct-pathway MSNs remained unchanged. A model of the striatal microcircuit revealed that such increases in FS innervation were effective at enhancing synchrony within targeted cell populations. These data suggest that after dopamine depletion, rapid target-specific microcircuit organization in the striatum may lead to increased synchrony of indirect-pathway MSNs that contributes to pathological network oscillations and motor symptoms of PD.
authors: Gladstone Institute of Neurological Disease, University of California, San Diego, La Jolla, CA 92093, USA.
authors: Aryn H
authors: AH
authors: Gittis
authors: Giao B
authors: GB
authors: Hang
authors: Eva S
authors: ES
authors: LaDow
authors: Liza R
authors: LR
authors: Shoenfeld
authors: Bassam V
authors: BV
authors: Atallah
authors: Steven
authors: S
authors: Finkbeiner
authors: Anatol C
authors: AC
authors: Kreitzer
mesh_terms: D000200:Action Potentials / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D001369:Axons / Q000378:metabolism / Q000648:ultrastructure; D001552:Benzazepines / Q000494:pharmacology; D001703:Biophysics; D003198:Computer Simulation; D003342:Corpus Striatum / Q000166:cytology* / Q000187:drug effects; D003891:Desipramine / Q000494:pharmacology; D004298:Dopamine / Q000172:deficiency*; D018492:Dopamine Antagonists / Q000494:pharmacology; D004558:Electric Stimulation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D066298:In Vitro Techniques; D007395:Interneurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D008239:Lysine / Q000031:analogs & derivatives / Q000378:metabolism; D051379:Mice; D008959:Models, Neurological; D009415:Nerve Net / Q000187:drug effects / Q000502:physiology*; D009433:Neural Inhibition / Q000187:drug effects / Q000502:physiology*; D016627:Oxidopamine / Q000494:pharmacology; D010320:Parvalbumins / Q000378:metabolism; D013469:Sulpiride / Q000494:pharmacology; D013565:Sympatholytics / Q000494:pharmacology; D013997:Time Factors; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D050495:Vesicular Inhibitory Amino Acid Transport Proteins / Q000378:metabolism
chemical_list: D001552:Benzazepines; D018492:Dopamine Antagonists; D004791:Enzyme Inhibitors; D010320:Parvalbumins; C534628:SCH 23390; D013565:Sympatholytics; D050495:Vesicular Inhibitory Amino Acid Transport Proteins; C492244:Viaat protein, mouse; D013469:Sulpiride; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; C013411:biocytin; D008239:Lysine; D003891:Desipramine; D004298:Dopamine